SYNBIOTIC Supports Industrial Hemp Liberalization and Cautions on Medical Cannabis Bill

SYNBIOTIC SE, a European medical cannabis and industrial hemp group, has expressed support for the Green Party's Industrial Hemp Liberalization Act proposal. This act aims to amend the Consumer Cannabis Act by removing the "intoxication clause," raising the THC limit for industrial hemp to 1%, and allowing indoor cultivation. This would align Germany with certain EU countries and could enhance the hemp sector's innovation and competitiveness.

The company believes the liberalization offers potential for sustainable agriculture and regional value creation. SYNBIOTIC is well-placed in the hemp market with subsidiaries like Hempro International. However, SYNBIOTIC is concerned about proposed changes to the Medical Cannabis Act, notably the restrictions on mail-order sales, which critics argue could hinder patient access.

SYNBIOTIC calls for balanced regulation to ensure quality healthcare and stresses the importance of both person-to-person and online healthcare solutions without broad bans.